It has been revealed in a new report that the largely growing unregulated clinical trial industry's drug trials in India had claimed many lives in the year ending June 2012. However, when it came to compensation of those lives, it promised only a measly amount of Rs. 2.2 lacs for each life.

As per the findings, some 668 and 438 lives were asked by the industry during clinical trials conducted in the years 2010 and 2011, respectively. But, the Serious Adverse Events (SAEs) reported the same as 22 in 2010, with some 16 deaths in 2011.

However, the same had reached up to 211 deaths in June 2012, the report finds. Lack of a proper reason for the deaths has probably caused the compensation amount to be so low. Since, in comparison to the figure this year, Rs 3.2 lakh were offered in a year prior to this one.

Besides, the paltry amount is also being endorsed to absence of any rules for compensation by the government. Though, according to Health Minister Ghulam Nabi Azad, guidelines regarding financial compensation have already been prepared. He has told that the guidelines are soon to be finalized as it is the right of trial subjects.